The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 20 de mayo del 1996
Philadelphia, PA, May 20, 1996 -- James O. Armitage, M.D., professor and chairman, Department of Internal Medicine, University of Nebraska Medical Center, today assumed the presidency of the American Society of Clinical Oncology (ASCO) during the Society's Annual Meeting.
An internationally-recognized oncologist, Dr. Armitage's research focuses on bone marrow transplantation, and the management and classification of lymphoma.
"The health care system in the U.S. is changing, and the impact on cancer patients is substantial," noted Dr. Armitage. "The advent of managed care puts at risk our ability to do clinical research, and thereby, advance cancer treatment. That scenario blurs the relationship of patients and their oncologist. ASCO needs to continue to be a leader in protecting the health and rights of cancer patients, and I'm confident that we will."
A member of ASCO's Board of Directors from 1988-1990, Dr. Armitage currently serves on the Board of the American Society for Blood and Marrow Transplantation and is chairman of its Clinical Affairs Committee. He is a past member of the board of the American Society of Hematology, and serves on numerous editorial boards including Annals of Oncology, Blood, and Leukemia and Lymphoma.
A member of ASCO's Board of Directors from 1989-1992, Dr. Mayer is also a member of the American Joint Committee on Cancer. He was a member of the American Board of Internal Medicine from 1985-1995. He serves on numerous editorial boards, including The New England Journal of Medicine, Harvard Medical School Health Letter, and Annals of Surgical Oncology.
Aug 30, 2012 - MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.